1,738
Views
4
CrossRef citations to date
0
Altmetric
CME/CE Spotlights

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Highlights from a CME symposium held at the Cardiometabolic Health Congress (CMHC) Sheraton Boston Hotel, Boston, MA, USA, 23 October 2015

, , &

Figures & data

Figure 1. (a) and (b). Normal function of PCSK9 is to promote degradation of LDL receptors. Adapted from reference [Citation8].

LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; mRNA, messenger ribonucleic acid; PCSK9, proprotein convertase subtilisin/kexin type 9.

Figure 1. (a) and (b). Normal function of PCSK9 is to promote degradation of LDL receptors. Adapted from reference [Citation8].LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; mRNA, messenger ribonucleic acid; PCSK9, proprotein convertase subtilisin/kexin type 9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.